(150 days)
No
The description focuses on the material properties, manufacturing process (lathe cut), and physical parameters of the contact lenses. There is no mention of any software, algorithms, or data processing that would suggest the use of AI/ML. The performance studies are related to material biocompatibility and equivalence to predicate devices, not algorithmic performance.
No.
The device is indicated for correction of refractive error and management of irregular corneal conditions, which are not considered therapeutic interventions in the context of disease treatment.
No
The device is a contact lens intended for daily wear to correct refractive errors and manage irregular corneal conditions. Its purpose is corrective, not diagnostic.
No
The device description clearly states it is a rigid gas permeable contact lens, which is a physical hardware device, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the device is for the correction of refractive error in the eye. This is a therapeutic or corrective purpose, not a diagnostic one.
- Device Description: The description details the physical characteristics of a contact lens, which is a medical device used on the body, not a reagent or instrument used to examine specimens from the body.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.), detecting diseases or conditions through laboratory tests, or providing information for diagnosis.
IVD devices are used in vitro (outside the body) to examine specimens from the human body to provide information for diagnosis, monitoring, or screening. This device is used in vivo (on the body) for vision correction.
N/A
Intended Use / Indications for Use
The Acuity 85TM (oprifocon A) Rigid Gas Permeable Contact Lenses are indicated for daily wear for the correction of refractive error (myopia, hyperopia, presbyopia and/or astigmatism) in aphakic and non-aphakic persons with non-diseased eyes. The lenses may be prescribed for daily wear in otherwise non-diseased eyes that require a rigid contact lens for the management of irregular corneal conditions such as keratoconus, pellucid marginal degeneration, or following penetrating keratoplasty or refractive (e.g., LASIK) surgery.
Product codes
HQD
Device Description
The Acuity 85TM (oprifocon A) Rigid Gas Permeable Contact Lenses are daily wear rigid gas permeable contact lenses:
- in the power range of -20.00 to +20.00 diopters for sphere
- with base curves of 4.0 mm to 11.50 mm
- with base curve chord of 6.0 mm to 6.5 mm
- with diameter of 7.0 to 21.0 mm
The lens material (oprifocon A) incorporates an ultraviolet light absorber and lenses are lathe cut contact lenses in the following designs: spherical, toric, multifocal, and aspheric surfaces in visibility tinted material. The material from which these lenses are made and the contact lenses described herein are substantially equivalent to the Boston Equalens II Material and Contact Lenses (oprifocon A) as described in K022128. These devices will not be marketed with multiple components or any required accessories.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-Clinical Studies: The oprifocon A lens material manufactured by Acuity Polymers, Inc. has been tested and found to meet the biocompatibility requirements listed in the FDA Daily Wear Contact Lens Guidance Document, May 1994 and ISO 10993-1 (2009) for a surface device, limited contact. The chemical, mechanical and optical characteristics of the new lens have been shown to be equivalent to the predicate lenses.
Clinical Studies: Clinical studies for the Acuity 85TM (oprifocon A) material have been deemed as not necessary in support of clearance of this premarket notification as no new or additional questions of safety or effectiveness have been raised as a result of the preclinical testing and evaluation of the material.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 886.5916 Rigid gas permeable contact lens.
(a)
Identification. A rigid gas permeable contact lens is a device intended to be worn directly against the cornea of the eye to correct vision conditions. The device is made of various materials, such as cellulose acetate butyrate, polyacrylate-silicone, or silicone elastomers, whose main polymer molecules generally do not absorb or attract water.(b)
Classification. (1) Class II if the device is intended for daily wear only.(2) Class III if the device is intended for extended wear.
(c)
Date PMA or notice of completion of a PDP is required. As of May 28, 1976, an approval under section 515 of the act is required before a device described in paragraph (b)(2) of this section may be commercially distributed. See § 886.3.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized caduceus symbol, which is a staff with two snakes coiled around it, and three human profiles facing right. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the symbol.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
June 2, 2017
Acuity Polymers, Inc. James Bonafini, Jr. President & COO 1667 Lake Avenue, Suite 354 Rochester, NY 14615
Re: K170001
Trade/Device Name: Acuity 85 (Oprifocon A) Rigid Gas Permeable Contact Lens Regulation Number: 21 CFR 886.5916 Regulation Name: Rigid Gas Permeable Contact Lens Regulatory Class: Class II Product Code: HQD Dated: April 27, 2017 Received: Mav 3. 2017
Dear James Bonafini, Jr .:
This letter corrects our substantially equivalent letter of June 2, 2017.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR
1
Page 2 - James Bonafini, Jr.
Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation
(21 CFR Part 801), please contact the Division of Industry and Consumer Education at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"
(21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely.
Denise
for Malvina Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose, and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
2
Indications for Use
510(k) Number (if known) K170001
Device Name
Acuity 85TM (oprifocon A) Rigid Gas Permeable Contact Lens
Indications for Use (Describe)
The Acuity 85™ (oprifocon A) Rigid Gas Permeable Contact Lenses are indicated for daily wear for the correction of refractive error (myopia, bresbyopia and/or astigmatism) in aphakic and non-aphakic persons with nondiseased eyes. The lens may be prescribed in spherical and aspheric powers ranging from -20.00 D for daily wear. The lenses may be prescribed for daily wear in otherwise non-diseased eyes that require a rigid contact lens for the management of irregular corneal conditions such as keratoconus, pellucid marginal degeneration, or following penetrating keratoplasty or refractive (e.g., LASIK) surgery. The lens may be disinfected using a chemical disinfection system only.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ------------------------------------------------- | -- |
[X] Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.
3
510(k) SUMMARY
| 1. Date Prepared | December 29, 2016 |
|---|---|
| 2. Applicant's Name: | |
| and Address: | Acuity Polymers, Inc. |
| 1667 Lake Avenue, Suite 354 | |
| Rochester, NY 14615 | |
| (585) 458-8409 | |
| 3. Contact Person: | James A. Bonafini, Jr. President |
| Telephone: (585) 458-8409 | |
| E-Mail: Jim.bonafini@acuitypolymers.com | |
| 4. Identification of Device: | |
| Common Name: | Daily Wear Contact Lens |
| Proprietary Name: | Acuity 85™ (oprifocon A) RGP |
| Device Classification: | Lenses, Rigid Gas Permeable, Daily Wear Contact Lens; |
| Class II (21 CFR 886.5916) | |
| Device Product Code: | HQD |
| 5. Premarket Notification Number | not available |
| 6. Establishment Registration Number: | 3012228452 |
| 7. Owner Operator Number: | 10051193 |
-
- Description of the New Device
The Acuity 85™ (oprifocon A) Rigid Gas Permeable Contact Lenses are daily wear rigid gas permeable contact lenses:
- Description of the New Device
-
in the power range of -20.00 to +20.00 diopters for sphere ●
-
with base curves of 4.0 mm to 11.50 mm
-
with base curve chord of 6.0 mm to 6.5 mm ●
-
with diameter of 7.0 to 21.0 mm
The lens material (oprifocon A) incorporates an ultraviolet light absorber and lenses are lathe cut contact lenses in the following designs: spherical, toric, multifocal, and aspheric surfaces in visibility tinted material. The material from which these lenses are made and the contact lenses described herein are substantially equivalent to the Boston Equalens II Material and Contact Lenses (oprifocon A) as described in K022128.
4
These devices will not be marketed with multiple components or any required accessories.
9. Intended Use
The Acuity 85™ (oprifocon A) Rigid Gas Permeable Contact Lens are indicated for daily wear for the correction of refractive error (myopia, presbyopia and/or astigmatism) in aphakic and non-aphakic persons with non-diseased eyes. The lens may be prescribed in spherical and aspheric powers ranging from -20.00 D to +20.00 D for daily wear. The lenses may be prescribed for daily wear in otherwise non-diseased eyes that require a rigid contact lens for the management of irregular corneal conditions such as keratoconus, pellucid marginal degeneration, or following penetrating keratoplasty or refractive (e.g., LASIK) surgery. The lens may be disinfected using a chemical disinfection system only.
10. Predicate Devices:
The Acuity 85™ (oprifocon A) RGP contact lenses for daily wear are substantially equivalent to the Boston Equalens II (oprifocon A) Daily Wear Contact Lens (K022128). This lens was selected because it is made from an identical material and has optics designed to address the same Indications for Use.
11. Substantial Equivalence
Substantial equivalence is based on:
For design: The predicate lenses, the Boston Equalens II RGP lenses for daily wear, have a standard or reverse lens geometry with an anterior aspheric optic surface. The new lenses, the Acuity 85™ RGP lenses for daily wear have the same substantially equivalent standard or reverse geometry with an anterior optic surface design.
For material: The predicate lens materials are comprised of a siloxanyl fluoroitaconate copolymer (oprifocon A). The new lens material also is comprised of a siloxanyl fluoroitaconate copolymer (oprifocon A).
The new lenses in this submission therefore are substantially equivalent to the lenses cleared under K022128.
12. Non-Clinical Studies
The oprifocon A lens material manufactured by Acuity Polymers, Inc. has been tested and found to meet the biocompatibility requirements listed in the FDA Daily Wear Contact Lens Guidance Document, May 1994 and ISO 10993-1 (2009) for a surface device, limited contact. The chemical, mechanical and optical characteristics of the new lens have been shown to be equivalent to the predicate lenses.
5
13. Clinical Studies
Clinical studies for the Acuity 85™ (oprifocon A) material have been deemed as not necessary in support of clearance of this premarket notification as no new or additional questions of safety or effectiveness have been raised as a result of the preclinical testing and evaluation of the material.
14. Packaging
The primary lens container for shipping is a flat pack card. The lenses will not be sterilized by Acuity Polymers, Inc. prior to shipment to customers.
15. Relationship to Special Controls (Guidance)
This submission requires reliance upon a guidance document to describe the change and its relevance to current guidance. The FDA Daily Wear Contact Lens Guidance Document, May 1994, is the relevant document to which this submission is based. Clinical performance data is not necessary since the material and optical design of the new lenses is substantially equivalent to the material and optical design of the predicate lenses in K022128. Both the new lenses and the predicate lens feature identical aspheric anterior optics.
16. Manufacturing & Packaging:
Finished Product Manufacturing, Inspection, Packaging and Distribution: Acuity Polymers. Inc. (Est. Regis: #3012228452) 1667 Lake Avenue, Suite 354 Rochester, NY 14615 (585) 458-8409
17. Action Taken to Comply with FDA Special Controls:
The submission is for a daily wear contact lens, Class II subject to Special Controls. The Special Control is the FDA Daily Wear Contact Lens Guidance Document. May 1994 to which this submission is applied. All testing listed in this 510(k) submission is in accordance with that document.
6
Side-by-Side Comparison
| NEW LENS | PREDICATE LENS | |
|---|---|---|
| Lens Characteristics | Acuity 85TM (oprifocon A) RGP Lens | Boston Equalens II (oprifocon A) RGP Lens |
| Manufacturer | Acuity Polymers, Inc | Bausch + Lomb |
| Material | oprifocon A | oprifocon A |
| Production method | Lathe Cut | Lathe Cut |
| UV Blocking | Yes | Yes |
| Base Curves (varies with vault) | 4.0 mm to 11.5 mm | 4.0 mm to 11.5 mm |
| Base Curve Chord | 6.0 mm to 6.5 mm | 6.0 mm to 6.5 mm |
| Design | Standard & reverse geometry with anterior | |
| aspheric surface | Standard & reverse geometry with anterior | |
| aspheric surface | ||
| Diameters: | 7.0-21.0 mm | 7.0-21.0 mm |
| Power Range | -20.00D to +20.00D | -20.00D to +20.00D |
| Astigmatism range corrected | Up to 9.00 D | Up to 9.00 D |
| Add Powers (for multifocal) | +1.00 D to +4.00 D | +1.00 D to +4.00 D |
| Indications for Use | The Acuity 85TM (oprifocon A) Rigid Gas | |
| Permeable Contact Lenses are indicated | ||
| for daily wear for the correction of | ||
| refractive error (myopia, hyperopia, | ||
| presbyopia and/or astigmatism) in aphakic | ||
| and non-aphakic persons with non- | ||
| diseased eyes. The lenses may be | ||
| prescribed for daily wear in otherwise | ||
| non-diseased eyes that require a rigid | ||
| contact lens for the management of | ||
| irregular corneal conditions such as | ||
| keratoconus, pellucid marginal | ||
| degeneration, or following penetrating | ||
| keratoplasty or refractive (e.g., LASIK) surgery. | The BOSTON EQUALENS II (oprifocon A) | |
| RGP contact lens is indicated for daily wear | ||
| for the correction of refractive ametropia | ||
| (myopia, hyperopia, astigmatism and | ||
| presbyopia) in aphakic and not-aphakic | ||
| persons with nondiseased eyes. | ||
| The lens may be disinfected using a | ||
| chemical disinfection system only. | ||
| Refractive Index (RGP) | $1.422 \pm 0.002$ | 1.423 |
| Oxygen Permeability (RGP | ||
| Center) | $115 \pm 24$ | 85 |
| Specific Gravity (RGP) | $1.23 \pm 0.02$ | 1.24 |
| Hardness (Shore D) | 81 | 80 |
| Modulus (MPa) | 1378 | 1300 |
| Tint | Visibility Tints – various | |
| D&C Green #6, D&C Violet #2, Solvent | ||
| Yellow 18 | Visibility Tints - various | |
| D&C Green #6, D&C Violet #2, Solvent | ||
| Yellow 18 | ||
| Water Content |